Skip to content
Triangle logo TriangleGet started
← Study library

NCT02232516 · REGISTRY CONDITION SEARCH

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2026-06-12

The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer. Currently, there is no standard treatment for patients with PTCL; the most common treatment used is a combination of drugs called CHOP, but this can be a difficult treatment to tolerate because of side effects, and is not particularly effective for most patients with PTCL. Romidepsin (Istodax®) is a type of drug called an HDAC inhibitor. It interacts with DNA (genetic material in cells) in ways that can stop tumors from growing. It is given as an infusion through the veins. Lenalidomide (Revlimid®) is a type of drug known as an immunomodulatory drug, or IMID for short. This drug affects how tumor cells grow and survive, including affecting blood vessel growth in tumors. It is given as an oral tablet (by mouth).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Response Rate (ORR), as Defined Per Cheson Criteria

→

outcome · POSTED

Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Duration of Response, Defined Per Cheson Criteria

→

outcome · POSTED

Delay to Cytotoxic Chemotherapy

→

outcome · NOT POSTED

NM PET/CT vs. CT Imaging in PTCL

→

outcome · NOT POSTED

Validate a New Prognostic Model for Newly Diagnosed PTCL

→

outcome · NOT POSTED

Immunohistochemistry Profile

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically confirmed diagnosis of PTCL (using the most recent edition of the World Health Organization \[WHO\] Classification of Tumors of Hematopoietic and Lymphoid Tissues as guidance) including: * Anaplastic large cell lymphoma, anaplastic large cell kinase (ALK)-negative * Angioimmunoblastic T-cell lymphoma * Enteropathy-type T-cell lymphoma * Extranodal natural killer (NK)/T-cell lymphoma, nasal type * Hepatosplenic gamma-delta T-cell lymphoma * Peripheral T-cell lymphoma, unspecified (not otherwise specified \[NOS\]) * Transformed mycosis fungoides * Subcutaneous panniculitis-like T-cell lymphoma. * NOTE: Patients with adequate archived (well-preserved, formalin-fixed) biopsy tissue remaining will be required to submit a portion for exploratory studies; this is not optional if tissue is available; however, lack of adequate tissue for exploratory studies will not preclude patients from participating * Patients must have bi-dimensionally measurable disease (\>= 1 cm) by CT imaging * NOTE: Patients with marrow-only disease are eligible; response for these patients will be assessed by repeat bone marrow biopsy * Patients must fit into one of the following categories: * Age \>= 18 years to \< 60 years with a cumulative illness rating scale (CIRS) score \>= 6 OR deemed ineligible for cytotoxic chemotherapy by the treating investigator * \>= 60 years * Patients must have adequate organ and marrow function (documented within 14 days prior to registration) as outlined below: * Absolute neutrophil count (ANC) \>= 750/mcl * Hemoglobin \>= 8 g/dl * Platelets \>= 50,000/mcl * Total bilirubin =\< 2 x upper limit normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum pyruvate glutamate transaminase \[SPGT\]) =\< 3 x ULN * Creatinine =\< 2 x ULN * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * All patients must agree to use effective contraception while on study, and all patients must agree to undergo counseling sessions every 28 days about pregnancy precautions and risks of fetal exposure * Females of childbearing potential (FCBP) must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide, during lenalidomide therapy, during dose interruptions, and for at least 28 days following discontinuation of lenalidomide therapy * Males receiving lenalidomide must agree to use a latex condom during any sexual contact with FCBPs even if they have undergone a successful vasectomy * NOTE: A FCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months) * FCBP should be referred to a qualified provider of contraceptive methods, if needed * FCPB must have a negative urine or serum pregnancy test within 7 days prior to registration, and be willing to adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS®) program * NOTE: Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Patients must be free of any prior malignancies for \>= 1 year * NOTE: The exception to this would be currently treated squamous cell and basal cell carcinoma of the skin, carcinoma in situ of the cervix, breast, or bladder, or surgically removed melanoma in situ of the skin (stage 0) with histologically confirmed free margins of excision * All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program * Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration Exclusion Criteria: * Patients with a diagnosis of any of the following are not eligible: * Anaplastic large cell lymphoma, ALK-positive * Adult T-cell lymphoma/leukemia (ATLL) * Anaplastic large-cell lymphoma, primary cutaneous type * Precursor T-lymphoblastic lymphoma/leukemia * Mycosis fungoides/Sezary syndrome (except transformed Mycosis fungoides \[MF\]) * NK-cell leukemia * T-cell granular lymphocytic leukemia * T-cell prolymphocytic leukemia * Patients must not have received prior systemic therapy for PTCL (except for corticosteroids for 10 or fewer days at any dose, no washout period required as long as they discontinue prior to starting study therapy); NOTE: topical treatment may have been given for prior existence of cutaneous lymphoma that has since become systemic PTCL; however, these topical therapies should be stopped at time of registration * Patients who received chemotherapy (including monoclonal antibodies) or radiotherapy, administered for any condition, within 4 weeks prior to registration are not eligible * Patients who received prior exposure to any other histone deacetylase (HDAC) inhibitors or immunomodulatory (IMID) agents for any reason are not eligible * Patients receiving ongoing treatment with any other investigational agents are not eligible * Patients who have known central nervous system (CNS) involvement of lymphoma are not eligible * Patients who have an uncontrolled intercurrent illness including, but not limited to, any of the following are not eligible: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness/social situations that would limit compliance with study requirements * Patients with a known human immunodeficiency (HIV) infection are not eligible * Patients who are pregnant or actively nursing an infant are not eligible * Patients with a QT interval \> 500 msec (using the Bazett's formula) within 28 days prior to registration are not eligible
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: romidepsin
    2. Drug: lenalidomide
    3. Other: laboratory biomarker analysis
    label
    Treatment (romidepsin, lenalidomide)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (romidepsin, lenalidomide)
    description
    Given IV
    name
    romidepsin
    other Names
    1. FK228
    2. FR901228
    3. Istodax
    type
    DRUG
  2. arm Group Labels
    1. Treatment (romidepsin, lenalidomide)
    description
    Given PO
    name
    lenalidomide
    other Names
    1. CC-5013
    2. IMiD-1
    3. Revlimid
    type
    DRUG
  3. arm Group Labels
    1. Treatment (romidepsin, lenalidomide)
    description
    Correlative studies
    name
    laboratory biomarker analysis
    type
    OTHER
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
30
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    To evaluate the use of NM PET/CT vs CT imaging in PTCL, a review of the utilized imaging modalities during treatment as a tool of response assessment will be done. When both imaging modalities are chosen for a patient, response assessment will be compared.
    measure
    NM PET/CT vs. CT Imaging in PTCL
    time Frame
    Up to 3 years
  2. description
    Clinical biomarkers including age, race, histology, and stage as an assessment of prognosis. A points based system will be used to correlate with recently developed prognostic model.
    measure
    Validate a New Prognostic Model for Newly Diagnosed PTCL
    time Frame
    Up to 3 years
  3. description
    To investigate the tumor immunohistochemical profile to identify potential biomarkers associated with prognosis and treatment response. Archived tissue samples collected at baseline will be evaluated in order to determine how marker expression correlates with clinical outcome.
    measure
    Immunohistochemistry Profile
    time Frame
    Baseline
primary Outcomes
  1. description
    The endpoint for this objective will be objective response rate (ORR), defined per Cheson criteria. Response will be assessed by imaging after cycles 3 and 6, and then every 6 months thereafter. Response at 3 months (after cycle 3) will be used for purposes of the interim efficacy analysis.
    measure
    Objective Response Rate (ORR), as Defined Per Cheson Criteria
    time Frame
    Assessed after cycles 3 and 6, then every 6 months up to 3 years
secondary Outcomes
  1. description
    The frequency and severity of toxicity events will be evaluated. All adverse events will be summarized as to type, severity, frequency, timing and attribution. Grade 3 or greater AEs that occurred in at least 10% of the patients are reported here
    measure
    Incidence of Toxicity Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
    time Frame
    Evaluated once per cycle (1 cycle=28 days) up to 1 year.
  2. description
    l be progression-free survival (PFS) 1 and 3 years after start of treatment as well as the duration of response from start of therapy, defined per Cheson criteria.
    measure
    Progression-free Survival (PFS)
    time Frame
    Reported at 1 and 3 years after the start of treatment
  3. description
    Survival is defined as the duration of time from start of treatment to time of death, up to three years from the start of study treatment. Overall Survival (OS) is reported below as the proportion of patients who are alive at 1 and 2 years after starting treatment.
    measure
    Overall Survival (OS)
    time Frame
    Reported at 1 and 2 years after the start of treatment
  4. description
    The duration of overall response is measured from the time measurement criteria are met for Complete Remission or Partial Response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented.
    measure
    Duration of Response, Defined Per Cheson Criteria
    time Frame
    Assessed from start of therapy for up to 3 years
  5. description
    Time to first cytotoxic chemotherapy is defined as the time (in months) from start of study treatment to time of first dose of anti-neoplastic cytotoxic chemotherapy that is administered to treat lymphoma.
    measure
    Delay to Cytotoxic Chemotherapy
    time Frame
    Up to 1 year
Full study description
brief Summary
The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer. Currently, there is no standard treatment for patients with PTCL; the most common treatment used is a combination of drugs called CHOP, but this can be a difficult treatment to tolerate because of side effects, and is not particularly effective for most patients with PTCL. Romidepsin (Istodax®) is a type of drug called an HDAC inhibitor. It interacts with DNA (genetic material in cells) in ways that can stop tumors from growing. It is given as an infusion through the veins. Lenalidomide (Revlimid®) is a type of drug known as an immunomodulatory drug, or IMID for short. This drug affects how tumor cells grow and survive, including affecting blood vessel growth in tumors. It is given as an oral tablet (by mouth).
detailed Description
PRIMARY OBJECTIVES: I. To evaluate the efficacy of the combination of romidepsin plus lenalidomide in patients with previously untreated peripheral T-cell lymphoma (PTCL). SECONDARY OBJECTIVES: I. Evaluate the safety of the combination of romidepsin and lenalidomide. II. Further evaluate efficacy of the combination of romidepsin and lenalidomide. III. Evaluate the delay to cytotoxic chemotherapy. TERTIARY OBJECTIVES: I. Evaluate the use of Northwestern Medicine (NM) positron emission tomography (PET)/computed tomography (CT) vs CT imaging in PTCL. II. Validate a new prognostic model for newly diagnosed PTCL. III. Investigate the tumor immunohistochemical profile to identify potential biomarkers associated with prognosis and treatment response. OUTLINE: Patients receive romidepsin intravenously (IV) over 4 hours on days 1, 8, and 15 and lenalidomide orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression, inter-current illness that prevents further administration of treatment, unacceptable toxicity, patient decides to withdraw from study treatment (or study as a whole), or general or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the treating investigator. After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 3 years.
Source references
references
  1. citation
    Ruan J, Zain J, Palmer B, Jovanovic B, Mi X, Swaroop A, Winter JN, Gordon LI, Karmali R, Moreira J, Petrich AM, Pro B. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Adv. 2023 Oct 10;7(19):5771-5779. doi: 10.1182/bloodadvances.2023009767.
    pmid
    37327113
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-4f78ee2885376f8e53ce
      requested nct id
      NCT02232516
      primary nct id
      NCT02232516
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      5ee33f1f0b087d6d20125397ca7b10d0ac57bc653a4e85716f92360717ae4042
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-4f78ee2885376f8e53ce
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02232516
      occurrences
      1. context exact
        NCT02232516
        end
        11
        exact text
        NCT02232516
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/64/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      45e17222dbe09a88b44497c4fb5e5c4b917a35b92beb51078fe65bb3471541ec

    Preserved source evidence · Not medical advice